Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;52(2):191-195.
doi: 10.1007/s11055-022-01222-6. Epub 2022 Mar 18.

Postcovid-19 Asthenic Syndrome

I A Zolotovskaia  1 , P R Shatskaia  1 , I L Davydkin  1 , O A Shavlovskaya  2
Affiliations

Postcovid-19 Asthenic Syndrome

I A Zolotovskaia et al. Neurosci Behav Physiol. 2022.

Abstract

Objective. To study the characteristics of asthenic syndrome and the potential for treating it in the postcovid period. Materials and methods. A continuous sampling method was used to select 129 patients (mean age 49.8 ± 8.9 years) after COVID-19. Study patients were selected at the clinical out-patient and polyclinic facilities in Samara in the period July-August, 2020. All patients signed informed consent. The envelope method was used to randomize patients into two groups: the study group (n = 64) received ethylmethylhydroxypyridine succinate (Neurox) 1 tablet (125 mg) three times daily for four weeks; medications in the reference group (n = 65) did not include any substances of the pharmacological antihypoxant/antioxidant/nootrope groups. Three visits (V) were made: the first (V1) was before inclusion in the study; the second (V2) was at 14 days; the third (V3) was on day 28 from treatment initiation. The dynamics of overall status (weakness, fatigue, concentration of attention, vertigo, headache, sleep impairment) were evaluated on a visual analog scale (VAS); the subjective perception of the severity of asthenia (tiredness, physical and mental fatigue, decreased motivation and activity) was evaluated using the Multidimensional Fatigue Inventory, MFI-20); cognitive functions were assessed using the Mini Mental State Examination (MMSA); and autonomic tone was assessed using the Kérdö index. Results. At the end of the study (V3), statistically significant changes in measures (VAS, MFI-20) were seen only in patients of the study group; the Kérdö Index showed no statistically significant differences. Analysis of MMSE data revealed a decline in cognitive functions in both groups, which may be linked with pseudocognitive deficit due to asthenia. Conclusions. Our studies yielded evidence of a high incidence of asthenic syndrome after COVID-19. Neurox decreased the severity and extent of the symptoms of asthenia.

Keywords: COVID-19; Neurox; asthenia; asthenic syndrome; postcovid period.

PubMed Disclaimer

References

    1. World Health Organization, Coronavirus Disease 2019 (COVID-19): Situation Report-55, WHO, Geneva (2020).
    1. Hozhabri H, Sparascio FS, Sohrabi H, et al. The global emergency of novel coronavirus (SARS-CoV-2): An update of the current status and forecasting. Int. J. Environ. Res. Public Health. 2010;17(16):5648. doi: 10.3390/ijerph17165648. - DOI - PMC - PubMed
    1. Yang Y, Peng F, Wang R, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J. Autoimmun. 2020;109:102434. doi: 10.1016/j.jaut.2020.102434. - DOI - PMC - PubMed
    1. Talotta R, Robertson E. Autoimmunity as the comet tail of COVID-19 pandemic. World J. Clin. Cases. 2020;8(17):3621–3644. doi: 10.12998/wjcc.v8.i17.3621. - DOI - PMC - PubMed
    1. Li C, Wang LL. Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection. Virus Res. 2020;286:198073. doi: 10.1016/j.virusres.2020.198073. - DOI - PMC - PubMed

LinkOut - more resources